Leqvio Compounded Equivalent: What Exists, What Doesn't, and How to Cut Costs

Why No Compounded Inclisiran Exists

There is no compounded version of inclisiran. This is not a temporary gap. It reflects the drug's molecular complexity.

Inclisiran is a synthetic double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc). That conjugation targets the molecule specifically to hepatocytes, where it silences PCSK9 messenger RNA through the RNA interference pathway 1. Compounding pharmacies, whether operating under FDA section 503A (patient-specific) or 503B (outsourcing facilities), work with small-molecule active pharmaceutical ingredients listed in the FDA's bulk drug substance catalog. Biologics and oligonucleotide therapeutics like inclisiran fall outside that catalog entirely.

The manufacturing process requires solid-phase oligonucleotide synthesis, GalNAc conjugation chemistry, HPLC purification, and sterility assurance at a scale no compounding pharmacy is equipped or licensed to perform 2. Even if the synthesis were theoretically possible, Novartis holds composition-of-matter patents on the inclisiran molecule and the GalNAc delivery platform that will not expire until the early 2030s.

Anyone advertising "compounded inclisiran" or an "inclisiran equivalent" is either misrepresenting the product or selling an unapproved substance. The FDA has issued warning letters to compounding pharmacies marketing unapproved versions of other injectable therapies; inclisiran would fall under the same enforcement posture 3.

What the ORION Trials Actually Showed

Inclisiran's efficacy data comes from the ORION clinical trial program. The numbers matter when deciding whether the cost is justified.

In ORION-10 (N=1,561, patients with ASCVD) and ORION-11 (N=1,617, patients with ASCVD or ASCVD risk equivalents), inclisiran 284 mg administered twice yearly reduced LDL-C by 52.3% and 49.9% respectively versus placebo at day 510 4. These reductions were durable across the dosing intervals, with no attenuation over 18 months.

ORION-9 focused on heterozygous familial hypercholesterolemia (N=482) and showed a 47.9% LDL-C reduction from baseline 5. Dr. Kausik Ray, lead investigator on ORION-11, stated: "The twice-yearly dosing schedule addresses one of the biggest barriers we see with PCSK9 monoclonal antibodies, which is adherence to every-two-week or monthly injections."

The ORION-4 cardiovascular outcomes trial (N=15,236) is evaluating whether these LDL-C reductions translate into fewer major adverse cardiovascular events. Results are expected in 2026. Until that readout, inclisiran's approval rests on LDL-C lowering as a surrogate endpoint, consistent with how the FDA handled the PCSK9 monoclonal antibodies evolocumab and alirocumab 6.

The Real Cost of Leqvio: WAC vs. Net Price

Sticker price and actual patient cost are very different numbers.

Novartis set Leqvio's wholesale acquisition cost at approximately $3,250 per injection, or $6,500 annually for the maintenance phase (two injections per year after the loading dose). In the first year, patients receive three injections (day 0, day 90, day 365), putting Year 1 WAC near $9,750. These figures come from wholesale pricing databases and Novartis investor communications 7.

The net price after rebates and discounts runs considerably lower for payers. Novartis has structured outcomes-based contracts with several large insurers that tie reimbursement to documented LDL-C lowering. For patients, the more relevant figure is their copay or coinsurance after insurance processes the claim.

Cash-pay patients without any insurance face the full WAC. Some specialty pharmacies list cash prices in the $540 range after manufacturer subsidies, but availability of that price depends on enrollment in Novartis patient support programs. Always confirm current pricing directly, as these programs change frequently.

Novartis Copay Card and Patient Assistance

The manufacturer copay program is the single most effective tool for reducing Leqvio cost.

Novartis offers the Leqvio Complete copay savings program for commercially insured patients. Eligible patients may pay as little as $0 per injection, with Novartis covering the difference between the patient's copay obligation and the program cap. The maximum annual benefit varies by plan year but has historically been structured to cover the full patient responsibility for most commercial plans 8.

Eligibility requirements include: commercial (non-government) insurance, a valid prescription for an FDA-approved indication, and U.S. residency. Patients covered by Medicare, Medicaid, TRICARE, or VA benefits do not qualify for the copay card. This is a federal anti-kickback statute restriction, not a Novartis policy choice.

For uninsured patients, Novartis operates a separate Patient Assistance Program (PAP) that may provide Leqvio at no cost. Income thresholds typically apply. The 2024 Endocrine Society Clinical Practice Guideline on lipid management notes that "access programs from manufacturers should be considered as part of the treatment decision when PCSK9-targeted therapies are appropriate but cost is a barrier" 9.

Key steps to enroll:

1. Your prescribing clinician submits the prescription to a Leqvio-enrolled specialty pharmacy or administers it in-office.
2. The Leqvio Complete team runs a benefits investigation on your behalf.
3. If commercially insured, the copay card is applied at the point of dispensing or billing.
4. If uninsured, the PAP application is initiated with income documentation.

Insurance Coverage: Medicare Part B, Commercial Plans, and Prior Authorization

Leqvio has a coverage advantage that most cholesterol drugs do not. It is billed under Medicare Part B.

Because inclisiran is administered by a healthcare professional (subcutaneous injection in-office), it qualifies as a physician-administered drug under Medicare Part B rather than Part D 10. This distinction matters enormously. Part B drugs have a 20% coinsurance after the Part B deductible ($240 in 2024), and Medicare Supplement (Medigap) plans often cover that 20%. A Medicare beneficiary with a Medigap plan could pay $0 out of pocket for Leqvio.

For commercially insured patients, coverage depends on the plan's formulary and medical benefit structure. Most large commercial payers cover Leqvio with prior authorization. The typical prior authorization criteria require:

• Documented ASCVD or HeFH diagnosis
• LDL-C above goal despite maximally tolerated statin therapy (usually defined as LDL-C >70 mg/dL for ASCVD or >100 mg/dL for primary prevention with HeFH)
• Trial of ezetimibe (some plans require this, others do not)
• Documentation that the patient has tried or has a contraindication to a PCSK9 monoclonal antibody (evolocumab or alirocumab)

That last criterion, the step-through requirement for a PCSK9 monoclonal antibody, is the most common reason for initial denial. A 2023 analysis in the Journal of Managed Care & Specialty Pharmacy found that 31% of initial PCSK9 inhibitor prior authorizations were denied, but 62% of appeals were successful 11.

If your prior authorization is denied, appeal. The appeal letter should reference the 2018 AHA/ACC cholesterol guideline recommendation that PCSK9-targeted therapy is reasonable for patients with clinical ASCVD whose LDL-C remains >70 mg/dL on maximally tolerated statin plus ezetimibe 12.

How Leqvio Compares to Other PCSK9 Options on Cost

The cost calculus between Leqvio, Repatha, and Praluent has shifted substantially since 2021.

Evolocumab (Repatha) carries a WAC of roughly $5,850 per year. Alirocumab (Praluent) is similar at approximately $5,400 annually. Inclisiran at $6,500 WAC appears more expensive on the surface, but the twice-yearly dosing (versus every 2 weeks or monthly for the monoclonal antibodies) reduces administration burden and may improve real-world adherence. A 2022 retrospective analysis in Circulation: Cardiovascular Quality and Outcomes found that only 55% of patients prescribed a PCSK9 monoclonal antibody remained adherent at 12 months 13.

Net cost after rebates and copay programs varies by payer. In practice, many commercially insured patients pay $0 for any of the three agents when manufacturer programs are applied. The meaningful cost difference emerges for Medicare patients: Leqvio under Part B with a Medigap supplement can result in $0 cost, while Repatha and Praluent under Part D may carry significant copays depending on the plan's formulary tier.

Dr. Seth Baum, past president of the American Society for Preventive Cardiology, has noted: "The Part B billing pathway for inclisiran is a genuine access advantage for Medicare beneficiaries who have struggled with Part D copays for the injectable PCSK9 antibodies."

What About Bempedoic Acid or Other Oral Options?

Patients priced out of PCSK9-targeted therapies sometimes pivot to oral alternatives. Bempedoic acid (Nexletol) is the most discussed.

Bempedoic acid reduces LDL-C by approximately 18% as monotherapy and 38% when combined with ezetimibe in the fixed-dose tablet Nexlizet 14. The CLEAR Outcomes trial (N=13,970) demonstrated a 13% reduction in major adverse cardiovascular events in statin-intolerant patients, making bempedoic acid the only non-statin oral LDL-lowering drug with a positive cardiovascular outcomes trial 15.

The WAC for Nexletol is approximately $4,800 per year, and for Nexlizet roughly $5,400. Generic bempedoic acid is not yet available. For patients who cannot access or afford inclisiran, bempedoic acid plus ezetimibe provides meaningful LDL-C lowering (roughly 38%) with proven cardiovascular benefit, though the magnitude of LDL-C reduction is smaller than the 50% seen with PCSK9 agents.

This is not an either-or decision. Guidelines support adding bempedoic acid or ezetimibe to maximally tolerated statin therapy before escalating to a PCSK9-targeted agent, and these oral therapies can be combined with inclisiran for patients who need aggressive LDL-C lowering 16.

Step-by-Step: Getting Leqvio at the Lowest Possible Cost

A systematic approach prevents overpaying.

Step 1: Confirm the indication. Leqvio is FDA-approved for adults with ASCVD or HeFH. Off-label use will not be covered by insurance and will not qualify for manufacturer programs.

Step 2: Maximize background therapy. Most payers require documentation that you are on a maximally tolerated statin (or have documented statin intolerance) and, in many cases, ezetimibe. Get these documented in your chart before the prior authorization is submitted.

Step 3: Have your clinician submit prior authorization proactively. Do not wait for a claim denial. Submit the PA with supporting documentation (LDL-C values, statin history, ezetimibe trial, diagnosis codes) upfront.

Step 4: Enroll in Leqvio Complete. Whether commercially insured or uninsured, enrollment in the Novartis support program should happen at the time of prescription. The program team handles benefits investigation and applies the copay card automatically.

Step 5: If denied, appeal within 30 days. Include a peer-to-peer review request. Reference AHA/ACC guidelines and your specific LDL-C values. The 62% appeal success rate means most denials are reversible.

Step 6: For Medicare patients, confirm Part B billing. Ensure your clinician's office bills Leqvio under Part B (HCPCS code J1305) rather than routing it through a specialty pharmacy under Part D. This single billing decision can change your cost from hundreds of dollars to zero with Medigap.

Verify all program details and eligibility directly with Novartis and your insurer, as terms change frequently. The most current copay card terms are available through the Leqvio Complete program or your prescribing clinician's office.